PMID- 36620821
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230111
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 14
IP  - 12
DP  - 2022 Dec
TI  - Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis (RA): A Retrospective 
      Study From Two Centers in Jeddah, Saudi Arabia.
PG  - e32240
LID - 10.7759/cureus.32240 [doi]
LID - e32240
AB  - BACKGROUND: Tofacitinib is the first Janus kinase (JAK) inhibitor approved for 
      treating rheumatoid arthritis (RA). Several clinical trials have evaluated the 
      safety and effectiveness of tofacitinib in adult patients with moderately to 
      severely active RA. Real-world studies provide invaluable insights into routine 
      clinical practice. We aim to assess the clinical efficacy and safety of RA 
      patients. METHODS: Over a period of two years, we included 50 consecutive RA 
      patients who were treated with tofacitinib. Clinical disease activity, assessed 
      by disease activity score (DAS) 28 - erythrocyte sedimentation rate (ESR), as 
      well as adverse events (AEs) were evaluated. RESULTS: A total of 50 patients (84% 
      female) were enrolled in the study. The mean age at initiation of tofacitinib was 
      48.54 +/- 15.97 years. The mean time of treatment with tofacitinib was 18.06 +/- 2.04 
      months. Patients were treated with tofacitinib 5 mg BID with 32% receiving 
      tofacitinib as monotherapy. A total of 74% of the patients had been prescribed at 
      least one biological treatment. The treatment target was achieved in 42 patients 
      (82%). Baseline characteristics and previous treatment regimens did not predict 
      clinical response to tofacitinib. Fifteen patients discontinued the treatment: 
      seven due to ineffectiveness, four due to pregnancy, and five due to adverse 
      events. The most common infectious adverse event was herpes zoster (4%) while the 
      most common observed laboratory abnormalities were elevation in low density 
      lipoprotein (LDL) and high density lipoprotein (HDL) in 6% and 8% of the 
      patients, respectively. CONCLUSION: Our results indicate that tofacitinib is 
      effective in real-world settings even as monotherapy. The treatment target was 
      attained by 82% of the patients on tofacitinib. The safety profile of tofacitinib 
      was generally consistent with previous studies.
CI  - Copyright (c) 2022, Alzahrani et al.
FAU - Alzahrani, Zeyad
AU  - Alzahrani Z
AD  - Rheumatology, National Guard Health Affairs, King Abdulaziz Medical City, Jeddah, 
      SAU.
FAU - Alhazmi, Ahmed
AU  - Alhazmi A
AD  - Rheumatology, King Fahad Armed Forces Hospital, Jeddah, SAU.
FAU - Almalki, Hanan
AU  - Almalki H
AD  - Rheumatology, King Fahad Armed Forces Hospital, Jeddah, SAU.
FAU - Aljehani, Noura
AU  - Aljehani N
AD  - Rheumatology, King Fahad Armed Forces Hospital, Jeddah, SAU.
FAU - Dumyati, Mohammed
AU  - Dumyati M
AD  - Internal Medicine, National Guard Health Affairs, King Abdulaziz Medical City, 
      Jeddah, SAU.
FAU - Alabdali, Hadeel
AU  - Alabdali H
AD  - Internal Medicine, King Abdulaziz Hospital, Mecca, SAU.
LA  - eng
PT  - Journal Article
DEP - 20221205
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC9813543
OTO - NOTNLM
OT  - low disease activity
OT  - remission
OT  - rheumatoid arthritis
OT  - safety
OT  - tofacitinib
COIS- The authors have declared that no competing interests exist.
EDAT- 2023/01/10 06:00
MHDA- 2023/01/10 06:01
PMCR- 2022/12/05
CRDT- 2023/01/09 04:19
PHST- 2022/12/05 00:00 [accepted]
PHST- 2023/01/09 04:19 [entrez]
PHST- 2023/01/10 06:00 [pubmed]
PHST- 2023/01/10 06:01 [medline]
PHST- 2022/12/05 00:00 [pmc-release]
AID - 10.7759/cureus.32240 [doi]
PST - epublish
SO  - Cureus. 2022 Dec 5;14(12):e32240. doi: 10.7759/cureus.32240. eCollection 2022 
      Dec.